Research Projects & Grants

Federal

• COG AAML1522 /Celgene CC -5013-AML-002: a phase 2, multicenter, single-arm, open-label study to evaluate the activity, safety and pharmacokinetics of Lenalidomide (Revlimid®) in pediatric subjects from 1 to less than or equal to 18 years of age with relapsed or refractory acute myeloid leukemia, Role: Investigator, Children Oncology Group, (01/2017 - 01/2018) Status: Completed
• COG-ACCL1131: A phase III open-label trial of caspofungin vs. azole prophylaxis for patients at high-risk for invasive fungal infections (IFI) following allogeneic hematopoietic cell transplantation (HCT), Role: Investigator, Children Oncology Group, (04/2016 - 04/2017) Status: Completed
• NCI - Special exception protocol for chimeric MOAB 14:18 (IND #4308, NSC 623408) pediatric patients, Role: Investigator, National Cancer Institute/NIH/DHHS, (09/2014 - 09/2015) Status: Completed
• COG-ANBL 12P1: pilot study using myeloblative Busulfan/Melphalan (BuMel) consolidation following induction chemotherapy for patients with newly diagnosed high-risk neuroblastoma, Role: Investigator, Children Oncology Group, (06/2014 - 06/2015) Status: Completed

For Profit Organization

• Pfizer FRAG-A001-201 (A6301094): A three month prospective open label study of therapy with Fragmin® ( Dalteparin sodium injection) in children with venous thromboembolism with or without malignancies, Role: Investigator, Pfizer Inc., U.S. Pharmaceuticals Group, (05/2017 - 05/2018) Status: Completed

Internal

• Tumor cell bank, Role: Investigator, LLU Dept. of Pediatrics, (04/2016 - 04/2017) Status: Completed